Vistagen Reports Fiscal Year 2024 Financial Results and Prov

11.06.2024 - Vistagen (Nasdaq: VTGN), a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, ...

Related Keywords

Japan , United States , America , , International Number Toll , Exchange Commission , B Development , Women Health Indications , Company Phase , Mental Health America Platinum Bell Seal , Fuji Pharma Co Ltd , Acute Treatment , Social Anxiety Disorder , Subjective Units , Distress Scale , Major Depressive Disorder , Key Pherine Mechanism , Positive Exploratory Phase , Data Study , Vasomotor Symptoms , Hot Flashes , Premenstrual Dysphoric Disorder , Mental Health America , Platinum Bell Seal , Cindy Anderson , Chief Financial , Exclusive Negotiation Agreement , Fuji Pharma , Fiscal Year , Dial In Number , South San Francisco , Annual Report , Ended March ,